All Posts: aging
-
More Evidence in Quest to Repurpose Cancer Drugs for Alzheimer’s Disease
TORONTO – An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer’s and Parkinson’s diseases when given to animals. This finding is the latest from Georgetown University Medical Center’s Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.
Category: News Release
-
Study: Cancer Drug Restores Brain Dopamine, Reduces Toxic Proteins in Parkinson, Dementia
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (July 11, 2016) — A small proof of concept study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson’s disease or dementia with Lewy bodies. Dopamine is the brain chemical (neurotransmitter) lost as a result […]
Category: News Release
-
Georgetown Alzheimer’s Researcher Has “BrightFocus”
(June 12, 2016) — Xiong Jiang, PhD, believes there is a way to identify patients at an early enough stage in Alzheimer’s disease — well before clinical symptoms crop up — that they could be effectively treated with novel agents. His ideas have earned him a 3-year $300,000 grant from the BrightFocus Foundation, and on […]
Category: GUMC Stories
-
Georgetown University and The Michael J. Fox Foundation for Parkinson’s Research Offer Fellowship in Regulatory Science
WASHINGTON and NEW YORK — Georgetown University Medical Center and The Michael J. Fox Foundation for Parkinson’s Research announce a fellowship in regulatory science that will promote postgraduate training in the Parkinson’s research field to optimize clinical trial design and support approval of novel therapies.
Category: News Release
-
“SNIFF,” a Nasal Insulin Study for Alzheimer’s, Now Underway at Georgetown
WASHINGTON – Georgetown University’s Memory Disorders Program is looking for volunteers to participate in a study to see if insulin, the hormone used to treat diabetes, can improve cognition, memory and daily function in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Category: News Release
-
Georgetown Study Opens for Those With Inherited Genetic Risk for Alzheimer’s Disease
WASHINGTON — The Memory Disorders Program at Georgetown University Medical Center is seeking volunteers to participate in a study testing two agents to slow the onset and progression of Alzheimer’s disease. Cognitively normal individuals with a particular genetic risk of developing the disorder are being sought.
Category: News Release
-
First Diagnosed Case of Alzheimer’s Disease in HIV-Positive Individual Reported
WASHINGTON (April 15, 2016) — Georgetown University researchers are reporting the first case of Alzheimer’s disease diagnosed in an HIV-positive individual. The finding in a 71-year-old man triggers a realization about HIV survivors now reaching the age when Alzheimer’s risk begins to escalate. Published online in the open access journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease […]
Category: News Release
-
Researcher Debunks Alzheimer's Prevailing Development Theory
(October 31, 2014) – New research that dramatically alters the prevailing theory of how Alzheimer’s disease develops has been published online today by Georgetown researchers in the journal Molecular Neurodegeneration. The research also helps explains why some people with plaque buildup in their brains don’t develop dementia, and shows the potential of a cancer drug […]
Category: GUMC Stories